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ARTICLE OPEN
Interactions between hippocampal activity and striatal
dopamine in people at clinical high risk for psychosis:
relationship to adverse outcomes
Gemma Modinos 1,2,3, Anja Richter1, Alice Egerton 1, Ilaria Bonoldi1, Matilda Azis 4, Mathilde Antoniades5, Matthijs Bossong6,
Nicolas Crossley7, Jesus Perez8,9,10, James M. Stone 1,2,11, Mattia Veronese 2, Fernando Zelaya2, Anthony A. Grace12,
Oliver D. Howes1,3,11,13, Paul Allen1,14 and Philip McGuire1,3,11
Preclinical models propose that increased hippocampal activity drives subcortical dopaminergic dysfunction and leads to
psychosis-like symptoms and behaviors. Here, we used multimodal neuroimaging to examine the relationship between
hippocampal regional cerebral blood flow (rCBF) and striatal dopamine synthesis capacity in people at clinical high risk (CHR) for
psychosis and investigated its association with subsequent clinical and functional outcomes. Ninety-five participants (67 CHR and
28 healthy controls) underwent arterial spin labeling MRI and 18F-DOPA PET imaging at baseline. CHR participants were followed up
for a median of 15 months to determine functional outcomes with the global assessment of function (GAF) scale and clinical
outcomes using the comprehensive assessment of at-risk mental states (CAARMS). CHR participants with poor functional outcomes
(follow-up GAF < 65, n= 25) showed higher rCBF in the right hippocampus compared to CHRs with good functional outcomes
(GAF ≥ 65, n= 25) (pfwe= 0.026). The relationship between rCBF in this right hippocampal region and striatal dopamine synthesis
capacity was also significantly different between groups (pfwe= 0.035); the association was negative in CHR with poor outcomes
(pfwe= 0.012), but non-significant in CHR with good outcomes. Furthermore, the correlation between right hippocampal rCBF and
striatal dopamine function predicted a longitudinal increase in the severity of positive psychotic symptoms within the total CHR
group (p= 0.041). There were no differences in rCBF, dopamine, or their associations in the total CHR group relative to controls.
These findings indicate that altered interactions between the hippocampus and the subcortical dopamine system are implicated in
the pathophysiology of adverse outcomes in the CHR state.
Neuropsychopharmacology (2021) 46:1468–1474; https://doi.org/10.1038/s41386-021-01019-0
INTRODUCTION
Two robust neurobiological findings in patients with psychosis are
alterations in the structure and function of the hippocampus [1–4],
and increased striatal dopamine synthesis capacity [5]. Moreover,
research in people at clinical high-risk (CHR) for psychosis suggests
that these findings are evident before the first episode of the
disorder ([2, 6–9], except [10]). These human findings are
consistent with data from preclinical studies, which also suggest
that increased hippocampal activity may drive dopamine dysfunc-
tion through projections to the striatum [11–13]. Contemporary
models propose that this interaction plays a critical role in the
development of psychosis-related behavioral phenotypes [14].
To date, relatively few studies have examined the relationship
between hippocampal activity and striatal dopamine function in
patients, partly because it entails the combination of MRI and PET
techniques in the same patient. Two studies that combined
functional MRI to assess task-related hippocampal activation and
18F-DOPA PET to measure striatal dopamine synthesis capacity
reported that the relationship between these measures in people
at CHR for psychosis was significantly different from that in
healthy controls [15, 16]. However, the patient samples were
small, and this precluded investigating whether changes in the
hippocampal-striatal relationship were associated with subse-
quent adverse outcomes. Here, we sought to address these issues
by studying hippocampal activity and dopamine function in a
larger CHR sample, and clinically monitoring the participants after
scanning to determine their clinical and functional outcomes.
Because preclinical data particularly implicate increases in resting
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hippocampal activity (as opposed to task-related activation), we
used pseudo-continuous arterial spin labeling (pCASL) MRI, which
indexes resting activity by measuring regional cerebral blood flow
(rCBF) [17].
Participants who had recently presented with a CHR state
and were largely medication-naïve were studied using pCASL and
18F-DOPA PET to measure hippocampal rCBF and striatal
dopamine synthesis capacity, respectively. After the two baseline
scans had been completed, participants were followed clinically to
determine their subsequent outcomes. Based on accumulating
evidence of significant poor functioning amongst CHR individuals
regardless of their transition to psychosis status or symptomatic
improvement [18–21], our outcomes of interest included clinical
and functional outcomes. We tested the hypothesis that within
the CHR sample, clinical and functional outcomes would be
related to the nature of the association between hippocampal
rCBF and striatal dopamine synthesis capacity at baseline.
MATERIALS AND METHODS
Participants
A total of 95 individuals were examined, comprising participants
from two larger independent studies (i.e., PROD and NEUTOP)
conducted at King’s College London. Supplementary Tables 1 and
2 show baseline sample characteristics by dataset. Both studies
used the same clinical and neuroimaging methods. Ethical
approval for both studies was obtained from the National Health
Service UK Research Ethics Committee, and all participants
provided written informed consent to participate according to
the Declaration of Helsinki.
CHR participants (n= 67) were recruited from two early
detection services: OASIS (outreach and support in South London
[22]), part of the South London and Maudsley NHS Trust; and
CAMEO (Cambridge early onset service), part of the Cambridge
and Peterborough NHS Trust. Inclusion criteria were: (i) meeting
operationalized criteria for CHR for psychosis, as determined with
the comprehensive assessment of at-risk mental states (CAARMS
[23]); (ii) no current/past diagnosis of psychotic/neurological
disorder assessed with the structured clinical interview for
diagnosis (SCID [24]); (iii) meeting Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition) criteria for substance
misuse or dependence disorder; and (iv) no contraindication to
MRI or PET scanning.
Healthy controls (HC, n= 28) were recruited from the same
geographical area and met the following inclusion criteria: no
personal/familial history of psychiatric/neurological disorder
assessed using the SCID [24]; no use of prescription medication
as assessed via self-report; not meeting Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition) criteria for substance
misuse or dependence disorder; and no contraindication to MRI or
PET scanning.
Clinical and functional measures
At baseline, all participants were assessed by the research team
with the national adult reading scale (NART [25]) to estimate
premorbid IQ, and the global assessment of functioning (GAF [26])
scale to measure overall social and occupational functioning.
Participants provided information on current cannabis use (yes/
no). In all CHR participants, the severity of psychotic symptoms
was evaluated using the CAARMS [23].
Subsequent to baseline, CHR participants were clinically
monitored in the community by an early detection team, which
provided practical and psychological support. Clinical and
functional outcomes were assessed in face-to-face interviews by
the research team after a median of 14.8 (interquartile range=
11.1–22.1) months. To examine overall functional outcome,
following previous studies [27–29] the CHR sample was dichot-
omized according to the GAF score at follow-up, with scores ≥65
defined as “good”, and scores <65 defined as “poor”. Transition to
frank psychosis was defined using the criteria in the CAARMS [23],
with the diagnosis confirmed using the SCID [24]. The change in
the severity of positive psychotic symptoms between baseline and
follow-up was calculated as follows [10]:
100 x
CAARMS positive rating at followup CAARMS positive rating at baselineð Þ
ðCAARMS positive rating at baselineÞ
pCASL
The pCASL acquisition parameters and preprocessing steps were
identical for both datasets, both acquired using the same General
Electric Signa HDX 3.0 T scanner at the Center for Neuroimaging
Sciences, King’s College London. These two pCASL datasets were
previously reported by our group in the context of separate
research questions (PROD [6]; NEUTOP [7]). Preprocessing steps
are described in detail in those previous publications as well as in
the Supplementary Methods. The resulting smoothed, normalized
individual CBF maps were used for analysis.
PET
PET imaging data were obtained on a GE Healthcare system
(Chicago, Illinois) for one dataset (PROD) and a Siemens Biograph
6 HiRez PET scanner (Erlangen, Germany) for the second dataset
(NEUTOP), in 3D mode. These two PET datasets were previously
published by our group in the context of separate independent
questions (PROD [30]; NEUTOP [10]). The PET data acquisition and
preprocessing procedures are explained in detail in those two
previous reports and in the Supplementary Methods. Our primary
measure was the whole striatal influx constant (Ki
cer, min−1). Time-
activity curves were visually inspected and Ki
cer was calculated
using the Patlak–Gjedde graphical approach adapted for a
reference tissue input function [31]. This approach has previously
been shown to have good reliability, with intraclass correlation
coefficients for the whole striatum of over 0.8 [32].
Harmonization of PET Data
Because the PET data were acquired with two different scanners,
we used ComBat [33–35] to harmonize the respective PET
datasets. The ComBat algorithm successfully removes unwanted
variation induced by scanner differences, while preserving
biological variability between individuals by using an empirical
Bayes framework [33–35]. Two advantages of this approach over
other methods are that it improves the removal of scanner effects
in datasets with small sample sizes, and does not make any
assumptions about the neuroimaging technique being used
[33, 36]. The ComBat software was accessed from GitHub
(https://github.com/Jfortin1/ComBatHarmonization) and the har-
monization algorithm was performed in R v3.6.0. In order to
preserve between-subject variability, the analysis included
age, sex, outcome group, CAARMS at baseline and at follow-up,
GAF at baseline, and at follow-up as covariates. Given preclinical
and clinical evidence of a potential effect of cannabis use on
dopamine synthesis and release [37–39], current cannabis use was
also included as a covariate in the ComBat analysis. By doing this,
the algorithm minimized any differences between the two
datasets that were not explained by any of these variables.
Statistical analysis
Clinico-demographic variables were compared using independent
samples t-tests for continuous variables, and chi-square tests for
categorical variables using the statistical package for social
sciences (SPSS) version 26 (Chicago, IL). Significance was set at
p < 0.05 (two-tailed).
Global CBF. To exclude potential group differences in global CBF,
we extracted global CBF values from each participant and
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subjected them to an independent samples t-test in SPSS (IBM
corporation). The automatic software for ASL processing (ASAP)
2.0 toolbox [40] was used to extract average CBF values from the
ICBM-152 mask as obtained from the DARTEL toolbox, running in
Statistical Parametric Mapping version 12 (SPM12; https://www.fil.
ion.ucl.ac.uk/spm/), and thresholded to contain voxels with a
>0.20 probability of being gray matter.
Functional outcomes. To test our hypothesis pertaining to
functional outcomes in CHR individuals, we examined the
relationship between hippocampal rCBF and striatal dopamine
synthesis capacity by functional outcome group dividing the CHR
sample into two groups at follow-up: a good functional outcome
group (CHR-good; GAF ≥ 65) and a poor functional outcome group
(CHR-poor; GAF < 65). Individual Ki
cer values were entered as
regressors in a voxel-wise ANCOVA in SPM12 to examine group
differences in the relationship between whole striatal dopamine
synthesis capacity and hippocampal rCBF in CHR-poor compared
to CHR-Good individuals, including age, sex and mean global CBF
as covariates of no interest. Effects were considered significant at a
voxel-wise height threshold of family-wise error (FWE) p < 0.05
after small volume correction for region-of-interest analyses using
a pre-specified anatomical mask of the bilateral hippocampus,
derived from the WFU_Pickatlas toolbox (Supplementary Fig. 1).
For completeness, we also investigated whether the relationship
between hippocampal rCBF and striatal dopamine synthesis
capacity in the total CHR sample differed from HCs using an
analogous approach in SPM12 as described above.
Change in psychotic symptoms. To test our hypothesis pertain-
ing to clinical outcomes, we investigated whether the interac-
tions between hippocampal rCBF and striatal dopamine
synthesis capacity in CHR individuals at baseline would predict
a subsequent increase in the severity of psychotic symptoms by
using linear regression in SPSS. Individual values from sig-
nificant loci of interaction (cluster average) between hippocam-
pal rCBF and striatal dopamine were extracted from the
above ANCOVA using the MarsBar toolbox [41] in SPM12
and subjected to linear regression in SPSS, analyzing the
relationship with percent change in CAARMS positive symptoms
within the total CHR sample, independent of their GAF grouping
(p < 0.05).
Exploratory analyses. Additional exploratory analyses were con-
ducted using measures of dopamine function in striatal subdivi-
sions (limbic, associative, and sensorimotor [42]). We assessed (i)
group differences in dopamine function by striatal subdivision
using a multivariate GLM in SPSS, and (ii) and group × dopamine
function by striatal subdivision × hippocampal rCBF in SPM12, using
the same procedures as in the main interaction analysis above.
Furthermore, in view of evidence that resting perfusion abnorm-
alities in CHR individuals may be particularly marked in the
CA1 subregion of the hippocampus [1, 2, 43], we examined the
relationship between whole striatal dopamine synthesis capacity
and rCBF using separate masks for the bilateral CA1, CA2, CA3,
dentate gyrus, and subiculum in SPM12 (Supplementary Methods,
Supplementary Fig. 2). Finally, we also conducted the supplemental
analysis with other CHR outcome definitions (psychosis transition/
non-transition and CHR remission/non-remission based on follow-
up CAARMS scores [44]), which are reported for illustration
purposes in the Supplementary Methods and Results. As above,
all SPM12 analyses used a significance threshold of pfwe < 0.05.
RESULTS
Participants and demographics
All 95 participants received both PET and pCASL scans. There were
no significant differences between the CHR and HC groups in age,
sex, estimated premorbid IQ, or current cannabis use. As expected,
CHRs had lower levels of overall functioning (GAF score)
compared to HCs (Table 1). Most CHR participants were naïve to
antipsychotic medication (93%), and antidepressant-free (70%). Of
the 67 CHR participants, 50 were followed up clinically, while 17
were lost to follow-up. A comparison between these participants
showed no significant differences in clinico-demographic variables
(Supplementary Table 3).
Of the 50 CHR individuals with available follow-up data, 25 had
a good functional outcome (CHR-good), and 25 had a poor
functional outcome (CHR-poor) (Supplementary Fig. 3). No
significant differences were found in clinico-demographic vari-
ables (including medication or cannabis use) at baseline between
these groups (Table 1). At follow-up, the majority of these 50 CHR
participants remained antipsychotic-(90%) and antidepressant-
free (78%). Six individuals of the total CHR sample developed a
psychotic disorder during the follow-up period. There was no











T/F or χ2 P T/F or χ2 P
Age in years, mean (SD) 24.43 (4.43) 22.80 (4.23) 1.70 0.09 22.20 (4.53) 23.74 (3.96) −1.28 0.21
Sex (male), N 16 (57.1%) 40 (59.7%) 0.05 0.82 15 (60%) 15 (60%) 0.000 1.00
Years of education, mean (SD) 15.11 (3.07) 13.98 (2.43) 1.91 0.06 13.96 (2.35) 13.68 (2.64) 0.40 0.69
Premorbid IQ estimate 103.12 (11.70) 106.00 (10.75) −1.13 0.26 105.89 (10.10) 107.93 (11.01) −0.67 0.51
GAF, mean (SD) 88.13 (8.64) 58.31 (9.27) 14.55 <0.001 58.36 (10.37) 56.92 (9.07) 0.52 0.60
CAARMS Total, mean (SD) NA 41.53 (18.32) NA NA 38.71 (16.45) 43.29 (19.55) −.088 0.39
CAARMS Positive, mean (SD) NA 8.00 (3.58) NA NA 7.44 (3.86) 8.64 (3.66) −1.13 0.27
CAARMS Negative, mean (SD) NA 5.89 (3.65) NA NA 6.04 (3.91) 5.75 (3.51) 0.27 0.79
Antipsychotics, N NA 5 NA NA 3 0 3.19 0.07
Antidepressants, N NA 20 NA NA 8 8 0.000 1.00
Cannabis use, N 15 (53.6%) 34 (50.7%) 0.18 0.67 14 (56.0) 10 (40%) 1.28 0.26
Global rCBF, mean (SD) 277.86 (45.68) 268.57 (54.39) 0.63 0.43 271.64 (52.15) 261.50 (61.46) 0.40 0.53
Striatal Ki
cer, mean (SD) 0.0126 (0.001) 0.0128 (0.001) 0.82 0.37 0.0131 (0.001) 0.0127 (0.001) 1.93 0.17
CAARMS comprehensive assessment of the at-risk mental state, CHR clinical high risk, GAF global assessment of function, SD standard deviation.
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significant difference between the functional outcome subgroups
in the proportion of participants who had transitioned to
psychosis in each (2/25 in CHR-Good, 4/25 in CHR-Poor;
χ2= 0.758, p= 0.384).
Relationship between hippocampal rCBF, striatal dopamine, and
functional outcomes
We observed a significant interaction between rCBF, striatal
dopamine synthesis capacity, and group (CHR-good vs. CHR-poor)
in the right hippocampus (xyz: 40, −12, −24; k= 14; t= 3.56, z=
3.32, pfwe= 0.035, Fig. 1A). This effect was driven by a significant
negative association in the CHR-Poor subgroup (xyz: 38, −8, −24;
k= 20; t= 3.99, z= 3.66, pfwe= 0.012), which was absent in the
CHR-Good subgroup (pfwe > 0.05) (Fig. 1B). Excluding the three
CHR participants who had been treated with antipsychotics from
the analysis did not change the results (xyz: 38, −8, −24; k= 17;
t= 3.93, z= 3.60, pfwe= 0.015). The group interaction also
remained significant (F[1,44] = 4.872, p= 0.033) after assessing
the potentially confounding effect of current cannabis use
(Supplementary Table 4). There were no suprathreshold effects
in the left hippocampus.
Analyzing the data separately by imaging modality revealed that
the CHR-poor group had significantly higher rCBF in this right
hippocampal region compared to the CHR-good group (xyz: 40, −12,
−24; k= 17; t= 3.68, z= 3.42, pfwe= 0.026, Fig. 1C). No differences
were found in either global rCBF (F[1,48]= 0.395, p= 0.532), rCBF in
the left hippocampus (pfwe> 0.05), dopamine synthesis capacity in the
whole striatum (F[1,48] = 1.933; p= 0.171), or by subdivisions
(Supplementary Table 5, Supplementary Fig. 4).
The total CHR and HC groups did not differ in terms of global
rCBF (F[1,93]= 0.824, p= 0.366), total hippocampal rCBF or by
subfield (pfwe > 0.05), rCBF in the left hippocampus (pfwe > 0.05),
dopamine synthesis capacity in the whole striatum (F[1,94]=
0.824; p= 0.366) or by subdivisions (Supplementary Table 5,
Supplementary Fig. 5). No significant interactions were found
between hippocampal rCBF, striatal dopamine, and baseline
group status (total CHR vs HC; pfwe > 0.05).
Relationship to subsequent worsening of positive symptoms
We next examined the relationship between hippocampal-striatal
interactions and the subsequent worsening of positive symptoms.
The model showed a direct relationship between the individual
values extracted from the significant cluster of right hippocampal
rCBF x striatal dopamine interaction and percent change in
CAARMS positive symptoms across the total CHR sample (β=
0.296, R2= 0.087, df= 47, p= 0.041) (Fig. 2). This indicated that
the stronger the association between hippocampal rCBF and
striatal dopamine at baseline, the greater the worsening of
symptoms over the subsequent follow-up period. This effect
remained evident as a strong trend after CHR participants who
had been treated with antipsychotics (n= 3) were excluded from
the analysis (β= 0.288, R2= 0.083, df= 44, p= 0.055).
Exploratory analyses
Exploratory analyses using measures of dopamine synthesis
capacity from striatal subdivisions also identified significant group
interactions for the associative and the sensorimotor subdivisions.
In both cases, these were driven by negative associations with
right hippocampal rCBF in the CHR-Poor subgroup (Supplemen-
tary Results, Supplementary Fig. 6). Repeating the main analyses
using rCBF measures from hippocampal subfields revealed a
significant group interaction with whole striatal dopamine for the
right CA1. Similar to the finding for total hippocampal rCBF, this
reflected a negative association in the CHR-poor subgroup that
was not significant in the CHR-good subgroup (Supplementary
Results). Furthermore, separate rCBF-only group comparisons by
hippocampal subfields showed greater rCBF in the right CA1 in
CHR-poor compared to CHR-good (Supplementary Results). None
of these exploratory analyses revealed suprathreshold effects in
the left hippocampus or its subfields.
Fig. 1 Relationship between hippocampal activity, striatal dopamine synthesis capacity, and functional outcomes. A Significant group
(CHR-poor vs. CHR-good) × rCBF × striatal dopamine interaction in the right hippocampus (pfwe= 0.035), overlaid on a standard brain
template. B Scatterplot depicts within-group associations between hippocampal rCBF and striatal dopamine (CHR-good, blue circles, pfwe >
0.05; CHR-poor, orange triangles, pfwe= 0.015), with regression lines and 95% CIs. C Boxplots show increased rCBF in this right hippocampal
cluster in CHR-poor individuals compared to CHR-good (pfwe= 0.026). CHR-T, clinical high-risk individuals who subsequently transitioned to
psychosis.
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DISCUSSION
Our main finding was that adverse outcomes in CHR individuals
were related to the nature of the association between increased
hippocampal rCBF and striatal dopamine synthesis capacity at
baseline. Specifically, a poor functional outcome was linked to
elevated rCBF in the right hippocampus, and to a negative
association between rCBF in this region and striatal dopamine
synthesis capacity, compared to CHRs with a good outcome.
Furthermore, the relationship between rCBF in this right
hippocampal region and striatal dopamine function was also
linked to a worsening of positive symptoms subsequent to
scanning.
Preclinical studies have shown that hippocampal hyperactivity
may lead to striatal hyperdopaminergia and psychosis-like
behaviors, such as increased amphetamine-induced locomotion
[11–13]. Moreover, pharmacological [45, 46] and chemogenetic
[47] manipulations that normalize hippocampal hyperactivity can
correct aberrant dopamine neuron population activity in the
striatum [46]. Neuroimaging studies in people at CHR for psychosis
reported both increased hippocampal rCBF and hippocampal
blood volume compared to healthy controls [2, 6, 7], while
functional MRI studies found attenuated hippocampal responses
in CHR during memory [15] and salience processing [9] tasks.
Furthermore, increased hippocampal blood volume at baseline
has been linked to the transition to psychosis [2], is present in the
early stages of psychosis [48], and the longitudinal normalization
of hippocampal rCBF has been associated with remission from the
CHR state [6]. Parallel work using PET reported elevated striatal
dopamine synthesis capacity in CHR individuals compared to
healthy controls ([30, 49, 50], except [10]), which was also found to
be linked to the onset of psychosis [51, 52], and to the worsening
of positive symptoms [10]. While there is thus independent
evidence for both altered hippocampal and dopaminergic
function in the CHR state, the relationship between them is less
clear. Two studies reported that the correlation between task-
related hippocampal activation and striatal dopamine in CHR
individuals was significantly different from that in healthy controls,
being negative as opposed to positive [15, 16]. These were cross-
sectional studies in small CHR samples, precluding investigation of
the extent to which changes in the hippocampal-striatal relation-
ship are linked to subsequent adverse outcomes. Our study
addressed this issue by studying a larger sample of CHR
individuals with both pCASL and 18F-DOPA PET who had been
followed up after scanning to determine their clinical and
functional outcomes. Our main hypothesis, that an altered
relationship between hippocampal rCBF and striatal dopamine
function would be associated with adverse outcomes, was
confirmed: a negative association between heightened hippo-
campal rCBF and striatal dopamine was linked to a poor functional
outcome and to an increase in the severity of psychotic
symptoms. Moreover, exploratory analyses of hippocampal sub-
fields indicated that these findings were particularly evident in the
CA1 subregion, and in the associative and sensorimotor subdivi-
sions of the striatum, supporting evidence implicating the
CA1 and the associative striatum as key foci of dysfunction in
psychosis [2, 5, 43, 53, 54].
The direction of the altered relationship between hippocampal
rCBF and striatal dopamine function in CHR-poor individuals was
negative. Given the evidence that both hippocampal activity and
dopamine function are elevated in CHR individuals, and the notion
that one drives the other, one might have expected adverse
outcomes to be linked to a positive correlation between these
measures. Our findings indicate that, in CHR individuals with a
poor functional outcome, those with greater hippocampal rCBF
showed lower striatal dopamine synthesis capacity. One possibility
is that these findings may challenge the main assumption, derived
from preclinical models, of a causal relationship between elevated
hippocampal activity and striatal dopamine in psychosis. Since
rodent studies have shown a clear positive relationship between
hippocampal activity and dopaminergic neuron function in a
system that operates at equilibrium [55, 56], another possibility is
that the observed negative correlation reflects a break-down of
this equilibrium, as this, in turn, was found to predict the
worsening of positive symptoms over time. The relationship
between hippocampal rCBF and striatal dopamine function in
humans may be non-linear or quadratic rather than linear, or it
indirect, involving additional subcortical regions such as the
nucleus accumbens, ventral pallidum, and the ventral tegmental
area [55, 57], as well as other neurotransmitter systems such as
glutamate or GABA [13, 58]. Longitudinal studies with serial
multimodal neuroimaging assays are warranted to establish the
direction of causality.
In contrast with previous findings, no significant differences in
striatal dopamine synthesis capacity between the total CHR group
and HCs were found [30, 49, 50]. This sample partially overlaps
with a previous study from our group which reported a similar
negative 18F-DOPA PET finding [10]. We also did not find a
significant difference in hippocampal rCBF between the CHR and
HC groups, in contrast to our previous findings in larger studies
that included the current cohorts [6, 7]. These differences may
reflect the larger numbers of individuals who subsequently
transitioned to psychosis during the follow-up period in those
previous studies. The sample size imbalance (67 CHR vs. 28 HC)
may also weaken the statistical inferences about group differences
for these analyses. However, this would not affect the results of
our primary analyses based on functional outcomes involving two
CHR subgroups of equal size. Overall, our findings extend prior
single-modality CHR studies indicating that an altered relationship
between hippocampal rCBF and striatal dopamine synthesis
capacity may be specific to CHR individuals with poor functional
outcomes, and could relate to the development of psychopathol-
ogy other than psychosis later in life (e.g., affective disorders) in
these individuals [59, 60]. Furthermore, it has been suggested that
poorer functioning may be independent of attenuated positive
symptoms in individuals at CHR for psychosis, following observa-
tions that individuals attaining remission from the CHR state may
continue to have poor functioning [19]. Further studies with
longer longitudinal follow-ups and a wider assessment of
comorbidities and psychopathology outcomes are required to
expand on the mechanisms underlying poor functional outcomes
in the CHR state.
Our findings should be considered in light of some limitations.
Although the PET data from the two datasets were acquired at the
Fig. 2 Relationship between hippocampal activity and striatal
dopamine function predicting the subsequent worsening of
positive psychotic symptoms. The scatterplot depicts a linear
regression in which percent change in baseline positive symptoms is
the dependent variable and the cluster-averaged values of the
rCBF × Ki interaction are the independent variable, with regression
lines and 95% CIs (p= 0.041). CHR-T, clinical high-risk individuals
who subsequently transitioned to psychosis.
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same center using the same methods, the scanner models were
different. We controlled for effects of the latter using ComBAT, a
robust method to remove unwanted technical variability induced
by scanner differences [35]. Because only a small number of
participants made a transition to psychosis (n= 6) or remitted
from the CHR state (n= 16), there was not sufficient power to
detect interactions between the baseline neuroimaging measures
according to other psychosis-relevant outcomes (reported for
illustration purposes in the Supplementary Methods and Results).
Future studies may explore associations with these other clinical
outcomes by conducting multimodal neuroimaging and follow-up
in a larger CHR sample, although this would be logistically
demanding, and would entail a multi-center design. A strength of
the study was that almost all of the CHR individuals were naïve to
antipsychotic medication, minimizing the likelihood of confound-
ing effects on the findings. Moreover, the exclusion of the small
number of participants who had been treated with antipsychotics
did not alter the main findings.
In conclusion, our findings suggest that adverse functional and
clinical outcomes in CHR individuals are linked to interactions
between elevated resting hippocampal activity and striatal dopa-
mine function, and support future research to examine the effect of
stabilizing hippocampal hyperactivity premorbid to prevent the
development of adverse outcomes in the CHR state [14].
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